This module uses fundamental data of GlaxoSmithKline PLC to approximate the value of its Beneish M Score. GlaxoSmithKline PLC M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out GlaxoSmithKline PLC Piotroski F Score and GlaxoSmithKline PLC Altman Z Score analysis.
GlaxoSmithKline
Beneish M Score
Market Cap
Enterprise Value
Price To Sales Ratio
Dividend Yield
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Invested Capital
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Payout Ratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Dividend Payout Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change To Inventory
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Dividends Paid
Sale Purchase Of Stock
Other Cashflows From Investing Activities
Change To Account Receivables
Stock Based Compensation
Investments
Net Borrowings
Total Cashflows From Investing Activities
Change To Operating Activities
Change To Netincome
Change To Liabilities
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Capital Stock
Short Term Debt
Common Stock
Retained Earnings
Accumulated Other Comprehensive Income
Intangible Assets
Other Liab
Long Term Debt
Good Will
Other Current Assets
Property Plant Equipment
Current Deferred Revenue
Other Assets
Net Receivables
Treasury Stock
Net Tangible Assets
Long Term Investments
Short Long Term Debt
Noncontrolling Interest In Consolidated Entity
Additional Paid In Capital
Long Term Debt Total
Capital Surpluse
Capital Lease Obligations
Non Current Liabilities Other
Net Invested Capital
Net Working Capital
Depreciation And Amortization
Interest Expense
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Selling General Administrative
Cost Of Revenue
Net Income Applicable To Common Shares
Minority Interest
Selling And Marketing Expenses
Net Income From Continuing Ops
Tax Provision
Interest Income
Discontinued Operations
Extraordinary Items
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
At this time, GlaxoSmithKline PLC's Cash Flow To Debt Ratio is quite stable compared to the past year. At this time, GlaxoSmithKline PLC's PB Ratio is quite stable compared to the past year. Free Cash Flow Per Share is expected to rise to 1.06 this year, although Book Value Per Share will most likely fall to 2.26.
At this time, GlaxoSmithKline PLC's M Score is unavailable. The earnings manipulation may begin if GlaxoSmithKline PLC's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by GlaxoSmithKline PLC executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of GlaxoSmithKline PLC's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if GlaxoSmithKline PLC's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between GlaxoSmithKline PLC's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards GlaxoSmithKline PLC in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find GlaxoSmithKline PLC's degree of accounting gimmicks and manipulations.
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Other Operating Expenses
15.33 Billion
At this time, GlaxoSmithKline PLC's Other Operating Expenses is quite stable compared to the past year.
GlaxoSmithKline PLC Earnings Manipulation Drivers
Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as GlaxoSmithKline PLC. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline PLC ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline PLC ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
The influence of GlaxoSmithKline PLC's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in GlaxoSmithKline. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to GlaxoSmithKline PLC's public news can be used to forecast risks associated with an investment in GlaxoSmithKline. The trend in average sentiment can be used to explain how an investor holding GlaxoSmithKline can time the market purely based on public headlines and social activities around GlaxoSmithKline PLC ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
GlaxoSmithKline PLC's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for GlaxoSmithKline PLC's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average GlaxoSmithKline PLC's news discussions. The higher the estimated score, the more favorable is the investor's outlook on GlaxoSmithKline PLC.
GlaxoSmithKline PLC Implied Volatility
33.78
GlaxoSmithKline PLC's implied volatility exposes the market's sentiment of GlaxoSmithKline PLC ADR stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if GlaxoSmithKline PLC's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that GlaxoSmithKline PLC stock will not fluctuate a lot when GlaxoSmithKline PLC's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GlaxoSmithKline PLC in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GlaxoSmithKline PLC's short interest history, or implied volatility extrapolated from GlaxoSmithKline PLC options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for GlaxoSmithKline Stock analysis
When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
Compare fundamentals across multiple equities to find investing opportunities
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.77)
Dividend Share
0.58
Earnings Share
2.97
Revenue Per Share
14.97
Quarterly Revenue Growth
0.092
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.